The challenge of new drug discovery for tuberculosis

Nature

Volumn 469, Issue 7331, 2011, Pages 483-490

  Koul, Anil ^a   Arnoult, Eric ^a   Lounis, Nacer ^a   Guillemont, Jerome ^a   Andries, Koen ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 1 A09; 1 AO9; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; ANTIBIOTIC AGENT; AX 20017; AZAMETHYLQUINOLONE; AZD 5847; BETA LACTAMASE INHIBITOR; BTZ 043; CAPREOMYCIN; CLOFAZIMINE; CPZEN 45; CYTOCHROME P450; ETHAMBUTOL; ISONIAZID; KANAMYCIN; MOLECULAR SCAFFOLD; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NXL 104; OXAZOLIDINONE DERIVATIVE; PNU 100480; PREGNANE X RECEPTOR; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

BACTERIUM; DISEASE CONTROL; DISEASE PREVALENCE; DRUG DEVELOPMENT; INNOVATION; LESION; TUBERCULOSIS;

BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BIOENGINEERING; CLINICAL TRIAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IN VIVO STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ANTITUBERCULAR AGENTS; CELL RESPIRATION; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; HOST-PATHOGEN INTERACTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; SIGNAL TRANSDUCTION; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 79251589638     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature09657     Document Type: Review

References (74)

1. Dye, C. & Williams, B. G. The population dynamics and control of tuberculosis. Science 328, 856-861 (2010)
2. Riley, R. L. Aerial dissemination of pulmonary tuberculosis. Am. Rev. Tuberc. 76, 931-941 (1957)
3. Barry, C. E. III et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Rev. Microbiol. 7, 845-855 (2009)
4. World Health Organization. Multidrug and Extensive Drug Resistant Tuberculosis: 2010 Global Report on Surveillance and Response (WorldhealthOrganization,2010)
5. Gandhi, N. R. et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375, 1830-1843 (2010)
6. Mitnick, C. et al. Community-based therapy formultidrug-resistant tuberculosis in Lima, Peru. N. Engl. J. Med. 348, 119-128 (2003)
7. Ma, Z., Lienhardt, C., McIlleron, H., Nunn, A. J. & Wang, X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 375, 2100-2109 (2010)
8. World Health Organization. The Global Plan to Stop TB 2011-2015: Transforming the Fight Towards Elimination of Tuberculosis (World Health Organization, 2010)
9. Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J. & Kivisto, K. T. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42, 819-850 (2003)
10. L'homme R. F. et al. Clinical experience with the combined use of lopinavir/ ritonavir and rifampicin. AIDS 23: 863-865; 2009.
11. Khachi, H., O'Connell, R., Ladenheim, D. & Orkin, C. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J. Antimicrob. Chemother. 64, 871-873 (2009)
12. Goodwin, B., Hodgson, E. & Liddle, C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56, 1329-1339 (1999)
13. Campbell, E. A. et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104, 901-912 (2001)
14. Burman, W. J., Gallicano, K. & Peloquin, C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin. Infect. Dis. 28, 419-429 (1999)
15. Touré, N.O. et al. Tuberculosis and diabetes [in French with English abstract]. Rev. Mal. Respir. 24, 869-875 (2007)
16. Dooley, K. E. & Chaisson, R. E. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect. Dis. 9, 737-746 (2009)
17. Ruslami, R. et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob. Agents Chemother. 54, 1068-1074 (2010)
18. Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Rev. Drug Discov. 6, 29-40 (2007).
19. Macielag, M. Chemical Properties of Antibacterial Drugs (45th Interscience Conference for Antimicrobial Agents and Chemotherapy (ICAAC), December 16-19, 2005)
20. Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998).
21. Working Group on New TB Drugs. The global TB drug pipeline. http://www.newtbdrugs.org/project.phpid5183 (2010).
22. Pethe, K. et al. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nature Commun. 1, 57 (2010)
23. Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223-227 (2005).
24. Koul, A. et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nature Chem. Biol. 3, 323-324 (2007)
25. Makarov, V. et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324, 801-804 (2009)
26. Bald, D.& Koul, A. Respiratory ATP synthesis: the newgeneration ofmycobacterial drug targets? FEMS Microbiol. Lett. 308, 1-7 (2010)
27. Koul, A. et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283, 25273-25280 (2008)
28. Rao, S. P., Alonso, S., Rand, L., Dick, T. & Pethe, K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, Nonreplicating Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 105, 11945-11950 (2008).
29. Boshoff, H. I. & Barry, C. E. III. Tuberculosis-metabolism and respiration in the absence of growth. Nature Rev. Microbiol. 3, 70-80 (2005).
30. Fischbach, M. A. & Walsh, C. T. Antibiotics for emerging pathogens. Science 325, 1089-1093 (2009)
31. Williams, K. N. et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53, 1314-1319 (2009)
32. Fortún J. et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 56: 180-185 (2005).
33. Conte, J. E. Jr, Golden, J. A., Kipps, J. & Zurlinden, E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob. Agents Chemother. 46, 1475-1480 (2002)
34. Singh, R. et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322, 1392-1395 (2008)
35. Manjunatha, U., Boshoff, H. I. & Barry, C. E. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun. Integr. Biol. 2, 215-218 (2009)
36. Chambers, H. F. et al. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob. Agents Chemother. 39, 2620-2624 (1995)
37. Hugonnet, J. E., Tremblay, L. W., Boshoff, H. I., Barry, C. E. III & Blanchard, J. S. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323, 1215-1218 (2009).
38. Drawz, S. M. & Bonomo, R. A. Three decades of b-lactamase inhibitors. Clin. Microbiol. Rev. 23, 160-201 (2010)
39. Agrawal, D., Udwadia, Z. F., Rodriguez, C. & Mehta, A. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int. J. Tuberc. Lung Dis. 13, 79-83 (2009)
40. O'Shea, R.& Moser, H. E. Physicochemical properties of antibacterial compounds: implications for drug discovery. J. Med. Chem. 51, 2871-2878 (2008).
41. Ritchie, T. J., Luscombe, C. N. & Macdonald, S. J. Analysis of the calculated physicochemical properties of respiratory drugs: can we design for inhaled drugs yet? J. Chem. Inf. Model. 49, 1025-1032 (2009)
42. Hett, E. C. & Rubin, E. J. Bacterial growth and cell division: a mycobacterial perspective. Microbiol. Mol. Biol. Rev. 72, 126-56 (2008)
43. Koul, A., Herget, T., Klebl, B. & Ullrich, A. Interplay between mycobacteria and host signalling pathways. Nature Rev. Microbiol. 2, 189-202 (2004)
44. Székely, R. et al. A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling. Immunol. Lett. 116, 225-231 (2008)
45. Miller, J. R. et al. A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc. Natl Acad. Sci. USA 106, 1737-1742 (2009)
46. Walburger, A. et al. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science 304, 1800-1804 (2004)
47. Zhou, B. et al. Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents. Proc. Natl Acad. Sci. USA 107, 4573-4578 (2010)
48. Kumar, D. et al. Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell 140, 731-743 (2010)
49. Keating, L. A. et al. The pyruvate requirement of some members of the Mycobacterium tuberculosis complex is due to an inactive pyruvate kinase: implications for in vivo growth. Mol. Microbiol. 56, 163-174 (2005)
50. Andries, K., Gevers, T. & Lounis, N. Bactericidal potencies of new regimens are not predictive for their sterilizing potencies in a murine model of tuberculosis. Antimicrob. Agents Chemother. 54, 4540-4544 (2010)
51. Dhar, N. & McKinney, J. D. Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice. Proc. Natl Acad. Sci. USA 107, 12275-12280 (2010)
52. Ibrahim, M., Truffot-Pernot, C., Andries, K., Jarlier, V. & Veziris, N. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am. J. Respir. Crit. Care Med. 180, 553-557 (2009)
53. Feldman, W. H., Karlson, A. G. & Hinshaw, H. C. Streptomycin in experimental tuberculosis: the effects in guinea pigs following infection in intravenous inoculation. Am. Rev. Tuberc. 56, 346-359 (1947)
54. Davis, J. M. & Ramakrishnan, L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 136, 37-49 (2009)
55. Russell, D. G., Barry, C. E. III & Flynn, J. L.Tuberculosis:whatwe don't knowcan, And does, Hurt us. Science 328, 852-856 (2010)
56. Donald, P. R. & Diacon, A. H. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinb.) 88 (suppl. 1), S75-S83 (2008)
57. Rustomjee, R. et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52, 2831-2835 (2008)
58. Wallis, R. S. et al. Biomarkers for tuberculosis disease activity, Cure, And relapse. Lancet Infect. Dis. 10, 68-69 (2010)
59. Mitchison, D. A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2months.Am. Rev. Respir. Dis. 147, 1062-1063 (1993).
60. Wallis, R. S. et al. Biomarkers and diagnostics for tuberculosis: progress, Needs, And translation into practice. Lancet 375, 1920-1937 (2010).
61. Diacon, A. H. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360, 2397-2405 (2009)
62. Rustomjee, R. et al. A Phase II study of the sterilising activities of ofloxacin, Gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12, 128-138 (2008)
63. Berry, M. P. et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973-977 (2010)
64. Spigelman, M., Woosley, R. & Gheuens, J. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, Not decades. Int. J. Tuberc. Lung Dis. 14, 663-664 (2010)
65. Pieters, J. Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe 3, 399-407 (2008)
66. Dhar, N. & McKinney, J. D. Microbial phenotypic heterogeneity and antibiotic tolerance. Curr. Opin. Microbiol. 10, 30-38 (2007)
67. Beresford, B. & Sadoff, J. C. Update on research and development pipeline: tuberculosis vaccines. Clin. Infect. Dis. 50 (suppl. 3), S178-S183 (2010)
68. Shi, L. et al.Changes in energymetabolismofMycobacteriumtuberculosis inmouse lung andunder in vitro conditions affecting aerobic respiration. Proc.Natl Acad. Sci. USA 102, 15629-15634 (2005)
69. Weinstein, E. A. et al. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. Proc. Natl Acad. Sci. USA 102, 4548-4553 (2005).
70. MOE. V. 2009. 10 http://www.chemcomp.com (Chemical Computing Group IncMontreal, Canada) (2010)
71. SIMCA-P112. Æhttp://www.umetrics.comæ (Umetrics AB, Umea?, Sweden) (2010).
72. Hirano, S., Ichikawa, S. & Matsuda, A. Structure-activity relationship of truncated analogs of caprazamycins as potential anti-tuberculosis agents. Bioorg. Med. Chem. 16, 5123-5133 (2008)
73. Hennessy, A. et.al. Substituted (Aza)-1 methyl -1H-Quinolin-2-ones as antibacterials. Patent W02010/046388A1 (2010)
74. Chao, M. C. & Rubin, E. J. Letting sleeping dos lie: does dormancy play a role in tuberculosis? Annu. Rev. Microbiol. 64, 293-311 (2010).